Defence Therapeutics Inc DTCFF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.28
- Day Range
- $0.28–0.28
- 52-Week Range
- $0.25–0.78
- Bid/Ask
- $0.24 / $0.40
- Shares Outstanding
- 75.79M
- Market Cap
- $16.01M
- Volume/Avg
- 11,581 / 7,811
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 5
Valuation
|
Metric
|
DTCFF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DTCFF
|
|---|---|
Quick Ratio | 3.36 |
Current Ratio | 3.37 |
Interest Coverage | −19.88 |
Quick Ratio
DTCFF
Profitability
|
Metric
|
DTCFF
|
|---|---|
Return on Assets (Normalized) | −168.29% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −275.46% |
Return on Assets
DTCFF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<>!bBy | LOCK|^$>j | $128B | |||
| Moderna Inc
MRNA
| LOCK|Q<tJZL | LOCK|FT | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|rZT<C? | LOCK|f?DT | $76B | |||
| argenx SE ADR
ARGX
| LOCK|nZC&MbG | LOCK|Y%& | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$bFkJRt | LOCK|#d& | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|bmHbqc | LOCK|>h%J^ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!&RyHTG | LOCK|QX&% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|B<g?&dq | LOCK|%& | $24B | |||
| Incyte Corp
INCY
| LOCK|sHg>Vx& | LOCK|<LZ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|gwqnG> | LOCK|n&b | $15B |
United States